Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · May 7, 2018

Keywords

ClinConnect Summary

This clinical trial is studying how the body processes a medication called liposomal amphotericin B (L-AmB) in two groups of patients: those who are critically ill and those who are not. The goal is to understand how the medication behaves in these different groups during early and late treatment periods. This information is important for improving treatment plans for patients with serious infections.

To participate in this study, patients must be receiving L-AmB and be admitted to either an Intensive Care Unit (ICU) or a hematology ward (where blood disorders are treated). However, pregnant or breastfeeding women, those who have previously had a bad reaction to L-AmB, or patients with specific do-not-resuscitate orders cannot join. Participants will be monitored closely during the trial, helping researchers gather valuable data that could enhance future treatments for patients with similar health conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Treatment with L-AmB
• • Admitted to an ICU or Hematology ward
• Exclusion Criteria:
• • DNR 2 or 3
• • Pregnant or lactating women
• • Previous documentation of intolerance/sensitivity to L-AmB